Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2017 1
2018 2
2021 1
2022 6
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2.
Stewart-Jones GBE, Elbashir SM, Wu K, Lee D, Renzi I, Ying B, Koch M, Sein CE, Choi A, Whitener B, Garcia-Dominguez D, Henry C, Woods A, Ma L, Montes Berrueta D, Avena LE, Quinones J, Falcone S, Hsiao CJ, Scheaffer SM, Thackray LB, White P, Diamond MS, Edwards DK, Carfi A. Stewart-Jones GBE, et al. Among authors: avena le. Sci Transl Med. 2023 Sep 13;15(713):eadf4100. doi: 10.1126/scitranslmed.adf4100. Epub 2023 Sep 13. Sci Transl Med. 2023. PMID: 37703353
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
Scheaffer SM, Lee D, Whitener B, Ying B, Wu K, Liang CY, Jani H, Martin P, Amato NJ, Avena LE, Berrueta DM, Schmidt SD, O'Dell S, Nasir A, Chuang GY, Stewart-Jones G, Koup RA, Doria-Rose NA, Carfi A, Elbashir SM, Thackray LB, Edwards DK, Diamond MS. Scheaffer SM, et al. Among authors: avena le. Nat Med. 2023 Jan;29(1):247-257. doi: 10.1038/s41591-022-02092-8. Epub 2022 Oct 20. Nat Med. 2023. PMID: 36265510
Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines.
Chalkias S, McGhee N, Whatley JL, Essink B, Brosz A, Tomassini JE, Girard B, Edwards DK, Wu K, Nasir A, Lee D, Avena LE, Feng J, Deng W, Montefiori DC, Baden LR, Miller JM, Das R. Chalkias S, et al. Among authors: avena le. J Infect Dis. 2024 Feb 13:jiae067. doi: 10.1093/infdis/jiae067. Online ahead of print. J Infect Dis. 2024. PMID: 38349280
Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.
Ying B, Scheaffer SM, Whitener B, Liang CY, Dmytrenko O, Mackin S, Wu K, Lee D, Avena LE, Chong Z, Case JB, Ma L, Kim TTM, Sein CE, Woods A, Berrueta DM, Chang GY, Stewart-Jones G, Renzi I, Lai YT, Malinowski A, Carfi A, Elbashir SM, Edwards DK, Thackray LB, Diamond MS. Ying B, et al. Among authors: avena le. Cell. 2022 Apr 28;185(9):1572-1587.e11. doi: 10.1016/j.cell.2022.03.037. Epub 2022 Mar 28. Cell. 2022. PMID: 35452622 Free PMC article.
Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domains.
Stewart-Jones GBE, Elbashir SM, Wu K, Lee D, Renzi I, Ying B, Koch M, Sein CE, Choi A, Whitener B, Garcia-Dominguez D, Henry C, Woods A, Ma L, Montes Berrueta D, Avena LE, Quinones J, Falcone S, Hsiao CJ, Scheaffer SM, Thackray LB, White P, Diamond MS, Edwards DK, Carfi A. Stewart-Jones GBE, et al. Among authors: avena le. bioRxiv [Preprint]. 2022 Oct 7:2022.10.07.511319. doi: 10.1101/2022.10.07.511319. bioRxiv. 2022. Update in: Sci Transl Med. 2023 Sep 13;15(713):eadf4100. doi: 10.1126/scitranslmed.adf4100. PMID: 36238717 Free PMC article. Updated. Preprint.
Fecal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) RNA Is Associated With Decreased Coronavirus Disease 2019 (COVID-19) Survival.
Das Adhikari U, Eng G, Farcasanu M, Avena LE, Choudhary MC, Triant VA, Flagg M, Schiff AE, Gomez I, Froehle LM, Diefenbach TJ, Ronsard L, Lingwood D, Lee GC, Rabi SA, Erstad D, Velmahos G, Li JZ, Hodin R, Stone JR, Honko AN, Griffiths A, Yilmaz ÖH, Kwon DS. Das Adhikari U, et al. Among authors: avena le. Clin Infect Dis. 2022 Mar 23;74(6):1081-1084. doi: 10.1093/cid/ciab623. Clin Infect Dis. 2022. PMID: 34245255 Free PMC article.
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant.
Scheaffer SM, Lee D, Whitener B, Ying B, Wu K, Jani H, Martin P, Amato NJ, Avena LE, Berrueta DM, Schmidt SD, O'Dell S, Nasir A, Chuang GY, Stewart-Jones G, Koup RA, Doria-Rose NA, Carfi A, Elbashir SM, Thackray LB, Edwards DK, Diamond MS. Scheaffer SM, et al. Among authors: avena le. bioRxiv [Preprint]. 2022 Sep 13:2022.09.12.507614. doi: 10.1101/2022.09.12.507614. bioRxiv. 2022. Update in: Nat Med. 2023 Jan;29(1):247-257. doi: 10.1038/s41591-022-02092-8. PMID: 36263060 Free PMC article. Updated. Preprint.
Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice.
Ying B, Scheaffer SM, Whitener B, Liang CY, Dmytrenko O, Mackin S, Wu K, Lee D, Avena LE, Chong Z, Case JB, Ma L, Kim T, Sein C, Woods A, Berrueta DM, Carfi A, Elbashir SM, Edwards DK, Thackray LB, Diamond MS. Ying B, et al. Among authors: avena le. bioRxiv [Preprint]. 2022 Feb 9:2022.02.07.479419. doi: 10.1101/2022.02.07.479419. bioRxiv. 2022. PMID: 35169795 Free PMC article. Preprint.
14 results